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Synergistic growth factor microenvironments
Manuel Salmero´n-Sa´nchez*a and Matthew J. Dalbyb
Growth factors (GF) are remarkably powerful signalling molecules that orchestrate developmental
biology. GFs are currently used in medical applications with limited success but it is clear that if their
potential can be harnessed for biomedicine then they could underpin the discipline of regenerative
medicine. However, while we understand that biology uses cell-secreted growth factors tethered to the
ECM, biologists typically employ GFs in soluble format at high concentrations. When used in vivo, this
causes oﬀ-target, unwanted eﬀects, which severely limits their use. There is a vast amount of literature
dealing with material systems that control the delivery of GFs. However, it was soon observed that GFs
could be more eﬀectively presented bound to surfaces from a solid-phase state rather than in soluble
form, recapitulating the way the extracellular matrix (ECM) binds GFs. In parallel, evidence was found
that within the ECM, GFs can actually work in cooperation with integrins and that this produced
enhanced GF signalling due to the crosstalk between both receptors. Recently this knowledge was used
to engineer microenvironments that target simultaneous integrin and GF receptor engagement seeking
to maximise GF eﬀects in vitro (e.g. in terms of stem cell diﬀerentiation) but also tissue repair in vivo
(e.g. bone regeneration and wound healing). This feature article introduces the concept of synergistic
GF/integrin signalling and then introduces GF delivery systems that were key in the development of
more advanced synergistic growth factor microenvironments.
1. Introduction
It is now well accepted that material-based approaches to control
stem cells hold great potential. Materials can be engineered to
deliver stimuli that regulate stem cell adhesion, signalling and
diﬀerentiation towards defined, desired, lineages. Stiﬀness, nano-
topography and chemistry are examples of material properties that
have been used to modulate the cellular microenvironment and
dictate stem cell fate.1–3 Key to achieving a desired therapeutic
outcome is the need to control the stem cell local environment, or
niche. However, our ability to engineer the complexity of this niche
in vitro has remained, until now, a major challenge.4,5
Growth factors (GF) are biomolecules that have strong
influence on cells, including stimulation of proliferation,
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migration and diﬀerentiation. Not only they are critical in
orchestrating embryonic development but also they are
involved in a range of physiological and pathological process,
including tissue homeostasis as well as repair and maintenance
(e.g. wound healing).6,7
In addition, GFs provide potent signals that have essential
influence on stem cell phenotype. For example, bone morpho-
genetic protein 2 (BMP-2) promotes osteogenesis; vascular
endothelial growth factor (VEGF) vascularisation and transforming
growth factor (TGF-b) chondrogenesis – GFs are important
biochemical cues that control stem cells.8
Because of this potential to regulate regenerative biology,
cocktails of GFs are traditionally used by biologists to control
stem cell diﬀerentiation in vitro.9 In addition, GFs are widely
used in clinical practice, with limited, and even controversial,
success which involved unwanted eﬀects including neurological
problems, ectopic bone formation and risk of cancer.10 This is
mainly because of the high, supraphysiological doses used in
order to achieve eﬀective local concentrations. However, if we look
to developmental biology, while the body indeed presents GFs to
natural stem cell niches in soluble forms secreted by cells, it
mainly, however, uses tethered signals coupled to the extracellular
matrix (ECM), allowing topical, low dose, administration.11,12
The controlled delivery of GFs has been used in combination
with biomaterial carriers with limited success and increasing
complexity of design has only produced small gains. The field
has evolved from sustained released of growth factors (e.g. from
hydrogels) to controlled GF binding to designed chemistries
using diﬀerent strategies, including covalent binding and
protein engineering.13,14 Significant diﬀerences in GF activity
and stability have been observed in dependence of soluble
versus bound presentation, which has led to the development
of surfaces that present physical and chemical cues that
regulate GF activity.15,16
Significant work has been developed to engineer novel
delivery systems inspired by the GF regulatory function of the
ECM, i.e. bioinspired systems that recapitulate the interactions
of GFs with components of the ECM. This includes heparan
sulphate proteoglycans, and proteins such as fibronectin, vitro-
nectin, tenascin C and fibrinogen. Seminal reviews addressing
ECM inspired materials to control GFs with applications in
bone regeneration, wound healing and angiogenesis have been
recently published.17–19 The interaction of GFs with the ECM is
so important that there has even been a new family of GFs
engineered to have super-affinity with the natural ECM.20
This feature article highlights recent development of
materials that present GFs in such a way that cell signalling
is synergistically enhanced by the formation of clusters between
integrins and GF receptors. Crosstalking between integrins and
GF receptors is known to maximise GF eﬀects in physiological
and pathological conditions.21 Engineering this dialogue
between integrins and GF receptors – synergistic growth factor
microenvironments – will have important translational con-
sequences as it has the potential to contribute towards significant
reduction in GF doses, maximising effects and safety in clinical
scenarios.
2. Growth factors and integrins
The way cells interact with their environment and perceive
physico-chemical changes comes via cell surface receptors.
Integrins are transmembrane receptors involved in cellular
adhesion, connecting the extracellular environment to the
cytoskeleton. Integrins are heterodimers containing two subunits
(a and b) that bind specifically a number of ligand peptides in the
ECM. For example, avb3 binds the well known arginine-glycine-
aspartic acid (RGD) sequence and a2b1 is one of the collagen
receptors.22 After integrin binding to the ECM, there is a process
of integrin clustering into supramolecular complexes called
focal adhesions which contain a number of structural and
signalling molecules that link the ECM to the actin cyto-
skeleton.23 Super-resolution microscopy has shown that integrins
and actin are vertically separated B40 nm by a layer of focal
adhesion proteins22 Within these structures, talin regulates the
nanoscale architecture of focal adhesions and integrin–talin–actin
complexes works as mechanical linkages (Fig. 1).24,25 Through
focal adhesions cells are able to feel the physical properties of the
ECM, such as stiffness; they are mechanoreceptors which
transduce physical signals, force in particular, into biochemical
and signalling cascades.26,27
GFs are proteins that modulate cell behaviour by regulating
signalling cascades to drive cell proliferation, morphogenesis
and diﬀerentiation. Cells interact with GFs via specific receptors
in their membrane with complex structure and dynamics. For
example, BMP-2 induces a complex at the plasma membrane of
type I and type II BMP receptors, allowing the receptors to
become phosphorylated and drive the down-stream signalling
cascades.29 Moreover, GF receptors are laterally mobile at the
plasma membrane and able to associate into microdomains to
enhance signalling.30 GF receptors are able to signal from the
membrane but are also able to be internalised in dependence of
Fig. 1 Integrins and focal adhesion. (a) The nanoscale structure of focal
adhesions including integrins bound to the ECM and focal adhesion
proteins that link the ECM to the actin cytoskeleton. (b) Staining of the
actin cytoskeleton and focal adhesion protein vinculin. The superposition
shows actin tethered to focal adhesion plaques. Reproduced with permission
from ref. 24 and 28.
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the localisation of the GF within the membrane and the way the
presentation of the ligand occur, i.e. binding of a soluble GF
might lead to endocytosis and signal modulation. Internalisa-
tion of the receptor–ligand complex is more difficult when GFs
are presented bound to a substrate (e.g. the natural ECM or
engineered material surfaces).31 Assembly of the ligand receptor
complex initiates phosphorylation of intracellular domains activat-
ing kinases and triggering downstream signalling. For example,
BMP-2 binding and receptor phosphorylation leads to the phos-
phorylation of intracellular Smad proteins which subsequently
hetero-oligomerize with Smad4 and translocate into the nucleus,
where they act as co-transcription factors with, e.g. runt related
transcription factor 2 (RUNX2 – the master bone transcriptional
regulator) to drive gene transcription that results in bone formation
(Fig. 2).29,32 This is known as canonical BMP signalling.
3. Crosstalk between integrins and
growth factor receptors
There is still a traditional view of the ECM as a reservoir of GFs that
can be released from the mesh of protein fibrils to function as
soluble ligands. However, there are several examples of GFs that
actually bind to their cell-based receptors as ‘solid phase’ ligands,
bound to the ECM. There are also increasing number of examples
of GFs binding to ECM proteins themselves, supporting the idea
that the presentation of GFs is an important function of the ECM.11
One of the primary functions of the ECM is to provide cells
with a network of proteins for integrin-mediated adhesion.12
The crosstalk between integrins and GFs was revealed in bio-
logical sciences more than a decade ago: cell adhesion is
necessary to implement activation of GF receptors, and then
GFs are necessary to stimulate cell adhesion, migration and
integrin-dependent signals.21 It is still an open question
whether this crosstalk between integrins and GF receptors
involves co-localisation of both proteins within the same region
within the cell membrane or only cooperation in the down-
stream signal pathway (Fig. 3).11,33
GF receptors can be activated through integrin association
leading to the formation of integrin–GF receptor clusters that
can trigger GF signalling even in the absence of GFs. For example,
mesenchymal stem cell (MSC) adhesion to fibronectin induced
a5b1 integrin dependent phosphorylation of PDGF receptor-b in
the absence of GFs. This synergistic relationship between integrins
and PDGF receptors was essential for MSC migration, which is a
physiological mechanism to recruit mesenchymal cells to sites of
vascular remodelling.35
Here, however, we are more interested in the importance of
direct physical interaction, i.e. co-localisation between integrins and
GF receptors, as this article is focused on how to engineer micro-
environments that recruit, in the same nanoscale cluster, both
receptors. For example, a5b1 forms a stable interaction with Tie2,
which is a receptor for Ang-1 (angiopoeitin-1) and the co-receptor
cluster is required for Ang-1mediated blood vessel formation in vivo
and enhancement of endothelial cell migration in vitro (Fig. 3).36 It
is interesting that this synergistic mechanism in vitro was only
enhanced when cells were plated on fibronectin and that this is
related to the ability of fibronectin to bind GFs next to the integrin
binding regions in a way that was described five years later, and as
will be discussed later.37 Integrin a5b1 bound to fibronectin has
been described to co-localise with other GF receptors, such as
receptors for bFGF, insulin and EGF to activate Rac and promote
endothelial cell-cycle progression. Using the same GFs with cells
attached on laminin (using a a2b1) the eﬀect of the GF was not
observed which led to the conclusion that physical interactions
and integration of both integrin and GF receptor signalling
localised to the same focal adhesions was needed.38 Notwith-
standing their role in biology to enhance signalling and control
physiological and pathological processes, precise molecular
details of the interaction between integrins and GF receptors
clusters still require elucidation.33,34,39
4. Presentation of growth
factors – looks matters
4.1. From surface bound GFs to engineered integrin/GF
microenvironments
As we have mentioned, in in vitro and in vivo experiments it is
still common to use GFs in solution either directly added to the
Fig. 2 Schematic representation of the classical action of soluble GFs
(e.g. BMP-2). BMP-2/receptor interaction promotes Smad phosphorylation
and translocation of transcription factors into the nucleus that lead to
diﬀerentiation and production of mature ECM. Reproduced with permission
from ref. 15.
Fig. 3 Diﬀerent mechanisms of interaction between integrins and GF
receptors (GFR). (a) Collaborative signalling means that often integrins
are required for GFR activation even after GF binding. (b) Integrins have
been reported to activate GFRs even in the absence of GFs (direct
activation). (c) Binding of integrin to the ECM in molecular proximity to
GFRs bound to GFs can induce the formation of stable integrin–GFRs
complexes that result in receptor crosstalk and synergistic signalling.
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culture media or released from a biomaterial carrier.13,40 This
thus ignores that GFs in vivo are bound to the ECM, both to
proteins and glycosaminoglcans.11 Solid-phase presentation of
GFs bound to a surface is more eﬃcient compared to soluble
administration, resulting in enhanced biological function
with lower doses used.8,17,18 Fig. 4 shows a sketch of classical
(soluble) vs. surface-bound presentation of GFs.
The pioneering work of Griﬃth et al. revealed that Epidermal
GF (EGF) could be tethered to surfaces retaining its biological
activity and with superior control of temporal and spatial avail-
ability in the extracellular matrix.16 They used star PEG on glass
on which EGF was conjugated and the superior eﬀect on
hepatocytes assessed. However, besides this remarkable success
that suggested an imminent change of paradigm in the way GFs
could be used – from soluble delivery tomatrix-bound presentation –
it took more than a decade to investigate the presentation of other
GFs from surfaces. Biotynilated IGF-1 was tethered on self-assembled
peptides which activated Akt, decreased the activation of caspase-3
and increased expression of troponin-I in cardiomyocytes
in vitro, as well as improved systolic function after infarction
in vivo.41 VEGF was shown to be retained within collagen gels
(through an ECM binding domain). This matrix bound VEGF
elicited prolonged activation of VEGF receptor VEGFR2 and
reciprocal responses on b1 integrin, a response which was
absent upon exposure to soluble VEGF.42 One of the first works
which showed the differential effect of surface-bound versus
soluble presentation of GFs on stem cells using EGF on glass
revealed that surface-tethered EGF promoted both cell spread-
ing and survival more strongly than saturating concentrations
of soluble EGF.43
Cavalcanti-Adam showed that matrix immobilised BMP-2
promoted cell migration and signalling compared to the
soluble delivery of BMP-2.45 To investigate the role of GF
density, they used block copolymer micelle nanolithography
to fabricate substrates with precise nanoscale distribution of
gold nanoparticles functionalised with BMP-2.46 They showed
that surface presentation of BMP was highly eﬃcient at triggering
the Smad-transcriptional pathway, when compared to soluble
administration of the GF. More so that surface-immobilized
BMP-2 at a concentration as low as 0.2 ng cm2 was still able to
induce Smad-dependent signalling due to local and sustained
presentation that did not perturb GF bioactivity. Segura et al.
showed that not only was important to have GFs presented from
surfaces but also that the density and organisation of GFs should
be considered to determine GF activity and eﬃciency bound to
surfaces.47 They immobilised VEGF to nanoparticles that were
loaded in a fibrinmatrix together with endothelial cells (HUVECs).
VEGF was bound in high and low densities to study the influence
of presentation in heterogeneous nanodomains with homo-
geneous distribution and they found the vascularisation
potential to increase in the high binding density format.47 This
result was related to the creation of GF reservoirs, mimicking
the physiological environment.11
Some of the pioneering works on ‘solid-phase’ presentation
of GFs used covalent tethering of GFs to surfaces.16 However,
exploiting the natural aﬃnity of ECM components (GAGs and
structural proteins) towards GFs has resulted in the development
of aﬃnity-based release systems, to control release of therapeutics
locally.48,49 In addition, aﬃnity-based systems allow engineering
‘solid-phase’ presentation of GFs that can be further internalised
by cells after binding, as this is key to activate certain signalling
pathways.31 Seeking to engineer localised GFs reservoirs, Picart
et al. showed that the well-known layer-by-layer (LbL) technique
using polyelectrolytes was a powerful and versatile strategy to work
as a delivery reservoir for BMP-2. LbL involves the use alternate
positive and negative charged molecules that are assembled into
layers.50 Picart et al. used poly(L-lysine)/hyaluronan (PLL/HA) poly-
electrolyte multilayer films to show that the amount of BMP-2
loaded in LbL films could be tailored by varying the film thickness,
i.e. the number of layers fabricated into the system, as well as the
concentration of the GF in the initial solution.51 They showed that
BMP-2 trapped in this LbL system was released to the media in
very low amounts and moreover it remained bioactive within the
film for more than 10 days to promote osteogenic diﬀerentiation
of C2C12 myoblasts.44 Interestingly, they showed that the activity
of the GF was related to the maintenance of its secondary structure
within the LbL film.52 This work fully supported the idea that GF
presentation rather than controlled delivery was key to enhance
the bioactivity of GFs. In addition to this, they showed, for the first
time, that presentation of GFs bound to biomaterial systems did
interfere with other physical properties of the ECM such as
mechanical stiﬀness.
Cells are known to respond to the stiﬀness of the environ-
ment. It has been shown that cells diﬀerentiate into osteoblast
on stiﬀ substrates (425 kPa) but not on soft ones (o10 kPa).53
Even when osteogenic media was used, cells were unable to
diﬀerentiate into osteoblast if the stiﬀness of the substrate
was too low.53 This reveals the importance of the physical
environment in cell behaviour. However, in a very elegant work,
Picart et al. showed that whereas on stiﬀ membranes cell
respond similarly to BMP-2, either bound to the surface
or soluble in the culture media, on soft films cells were
indeed responsive to matrix bound BMP-2 (but not to soluble
BMP-2).44 These experiments were key to reveal not only that
the eﬀect of GFs was more eﬀective if presented from surfaces,
but also that the interplay between diﬀerent receptors
Fig. 4 The scheme summarises the main diﬀerences between soluble vs.
solid-phase presentation of GFs. GFs presented from surfaces are spatially
confined and have limited diﬀusion. Even if the surface concentration of
GFs is low, they are presented in highly local concentrations and have the
potential to establish crosstalk with adhesion receptors.
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(e.g. integrins – mechanosensors able to discriminate matrix
stiffness54 – and GF receptors) was key in the design of
biomaterial systems.
The key role of the interplay between GFs presentation and
the physical properties of the synthetic matrix used as a vehicle
for GF presentation has been further demonstrated using
self-assembling peptide amphiphiles (PA). PA molecules can
self-assemble into supramolecular nanofibers that can be
designed to bind specific GFs.55 Recently, Stupp et al.modulated
intermolecular interactions within supramolecular assemblies
and their role in GF signalling. To do so, they designed two
systems that diﬀered in the degree of intermolecular hydrogen
bonding (choosing primary amino acid sequences with varied
b-sheet propensity) and found that the structures with weaker
internal cohesion significantly enhanced GF signalling and
osteogenic commitment using BMP-2. This was related to the
ability of these structures to promote enhanced raft mobility
within the cell membrane which in turn enhanced cell signalling.
This work identified a new mechanism – membrane mobility – as
a way to enhance the effect of GFs presented from biomaterial
nanofibers.56 It is interesting to note in a parallel work the
mobility of fibronectin adsorbed on polymers with different
chain dynamics has been correlated with cell adhesion and cell
differentiation.57
In relation to the interplay between GF delivery systems
and cell adhesion, it has been shown that the soluble admin-
istration of GFs was more eﬀective if cells were previously
targeted for integrins to bind specifically to the GF delivery
system. These works further revealed the importance of both
receptors in maximising GF eﬀects. For example, Garcia et al.
showed that protease-degradable hydrogels released controlled
amounts of VEGF that were more eﬀective in promoting
vascularisation in a rat subcutaneous implant when the hydrogel
had been functionalised with RGDmolecules.58 Integrin-modulation
of GFs eﬀects were also revealed in protease-degradable hydrogels
functionalised with a triple-helical, a2b1 integrin-specific peptide
(GFOGER) as a BMP-2 delivery system. These engineered hydro-
gels increased osteoprogenitor localization in the defect site,
enhanced bone formation and induced defect bridging and
mechanically robust healing at low BMP-2 doses.59 Importantly,
similar doses led to no bone regeneration when delivered from
simple collagen sponges.
Sobel et al. used recombinant fibronectin fragments to
identify the heparin II binding region of fibronectin (FNIII12–14)
as a VEGF binding site and reported that only bivalent fibronectin
constructs encompassing the integrin binding site and VEGF
binding domains significantly promoted endothelial migration,
proliferation and signalling.60 Building on this result, Martino
et al. showed that FNIII12–14 was actually a highly promiscuous
GF binding region able to sequester not only VEGF but also a
large number of GFs from different families (Fig. 5).37 They used
this information to produce a major breakthrough in the design
of material systems to present GFs; the concept of utilizing
crosstalk between integrins and GF receptors in a synthetic
system. To do so, they started with a fibrin matrix that was
functionalised with two recombinant fragments of fibronectin
pieced together. FNIII9–10,
61 which contains the well know RGD
site to promote cell adhesion, and FNIII12–14, the classical
heparin II binding site that promiscuously binds GFs37 (Fig. 5).
They showed that the resulting FNIII9–10/12–14 fragment fused
to the fibrin matrix induced in vitro tube-like structure formation
in endothelial cells using VEGF-A, smooth muscle cell sprouting
in response to PDGF-BB and mesenchymal stem cell (MSC)
differentiation towards osteogenic lineages using BMP-2.
Importantly, they also showed that the system worked in vivo
by promoting (a) skin healing (wound healing) in a diabetic
mice model using a combination of VEGF-A165 and PDGF-BB
and (b) bone regeneration in a critical size calvarial defect in
a skeletally mature rat using a combination of BMP-2 and
PDGF-BB.62 This work showed that the biological concept of
crosstalk between integrins and GF receptors used by ‘biology’
could actually be engineered into a material-based system that
could stimulate cell behaviour in vitro and promote tissue repair
in vivo. From a clinical perspective, it illustrated that significantly
lower doses of GFs could be effectively used to promote tissue
healing following tissue engineering principles. This material
Fig. 5 Engineered GF microenvironments based on FNIII12–14 incorpo-
rated in fibrin matrices. (a) Examples of GFs with affinity for FNIII12–14
measured by ELISA. Binding was promiscuous, known interactions shown
in black or white. Overall, more than 25 new interactions were described.
(b) The sketch shows a recombinant fibronectin fragment that consist of
FNIII9–10 (the integrin binding site) linked to FNIII12–14 (the GF binding
site) and a substrate sequence to be covalently bound into a fibrin matrix.
This engineered microenvironment promotes GF binding in synergy with
integrins and enhanced cellular processes. Reproduced with permission of
ref. 37 and 62.
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system incorporated B100 ng of GFs which was significantly
lower than the410 mg previously used to promote regeneration
in the samemodel.62 This work represented amajor landmark in
the way GFs had been used and put synergistic signalling in the
map as a way to use GFs efficiently and safely.
4.2. Integrins in engineered synergistic microenvironments
There is debate over which integrins are involved in the
adhesion/GF synergistic process and whether this depends on
the type of GF and/or the biomaterial system itself. Originally,
fibrin matrices modified with FNIII9–10/12–14 showed that the
synergy with GFs was principally mediated through a5b1 (versus
avb3, another important RGD receptor) as revealed by blocking
experiments with antagonistic antibodies (Fig. 6).62 However,
previous work had described a critical role of integrin avb3 in
physiological angiogenesis and the synergistic role with VEGF
receptor-2.63 Following from this earlier work suggesting a
major role for avb3, Traub et al. engineered FNIII10 (RGD
sequence without the PHSRN and so only ligates to avb3 and
not a5b1)
64 fused to VEGF-A165 in a fibrin matrix. This system
presents the GF in close apposition to the avb3 binding site of
fibronectin.65 They found that while HUVECs were able to bind
VEGF within the system and activate both VEGFR-2 and avb3,
the angiogenic response was reduced in comparison to the
pro-angiogenic effect of fibrin-immobilised VEGF only; inferring
a more important role for a5b1.
65
Similar behaviour was found using the heparin-binding
domain of fibrinogen incorporated into synthetic PEG matrices
as described next. Martino et al. showed that the fibrinogen
domain (Fg b15–66(2)) binds several GFs from the PDGF/VEGF
and FGF families and that incorporated together with RGD
(no synergy sequence and so avb3 binding only) into a PEG
hydrogel crosslinked with a MMP-degradable sequence, the sys-
tem was able to promote wound healing in a diabetic mouse.66
Rather unexpectedly, but in agreement with Traub et al.,65 they
obtained better wound healing when the RGD sequence was
removed from the matrix.66 This finding per se does not mean
that integrin binding is not involved in enhancing the role of GFs
to promote tissue healing but most likely that a5b1, being unable
to bind to RGD (as the synergy sequence was not included),67 was
not allowed to play its critical role in VEGF mediated wound
healing.62 Further experiments with this system including
integrin-specific fibronectin fragments are deemed necessary
to assess this hypothesis and fully establish the role of a5b1 in
cooperation with GF receptors.66
In an eﬀort to understand signalling mechanisms, including
integrin and GF receptors signals, as well as their interplay with
the physical properties of the matrix (stiﬀness), Albiges-Rizo
et al. investigated how matrix-bound BMP-2 activated the Smad
cascade in relation to co-ordinated integrin and BMP-2 receptor
signalling.68 They used LBL films made of poly(L-lysine) and
hyaluronan with modulated and controlled stiﬀness. Interestingly,
they found that BMP-2 receptors and b3 integrins (but not b1)
co-ordinately controlled cell spreading and Smad signalling, which
complicates the above described roles of b3 and b1 (Table 1).
Soluble GFs are non-eﬀective when cells are cultured on soft
matrixes, for example, BMP-2 cannot drive bone formation.
However, solid-phase GFs are eﬀective. BMP-2 presented in surface
bound format overrode the stiﬀness response of cells to soft
matrixes and permitted osteogenic diﬀerentiation. It is proposed
this occurs through actin and adhesion dynamics via cooperation
between both integrin and GF receptors. The authors concluded
that the presentation of matrix bound BMP-2 to receptors activated
the avb3 integrin hence mediating cell spreading and cell migra-
tion thanks to interactions that involved BMP-2 and fibronectin.
As there was no exogenous fibronectin in their system,
for this mechanism to occur, the authors hypothesised that
Fig. 6 Controversies in integrin activation in synergy with BMP-2. Both
a5b1 and avb3 have been reported to be involved in synergistic integrin/
BMP-2 receptor signalling. (a) MSC osteogenic diﬀerentiation with fibrin
matrix functionalised with fibronectin recombinant proteins (FNIII9–10 for
integrin binding, FNIII12–14 for GF binding and FNIII9–10/12–14 for
synergistic activation of receptors). Expression of osteoblastic genes by
qPCR. Note that osteogenic differentiation was prevented by blocking a5b1
but not affected by avb3. (b) Cells (C2C12) seeded on LbL soft films with
BMP-2 bound to the surface and stained for integrins b1, b3, a5, av. Inserts
show detail of focal adhesion structures containing these integrin subunits.
(c) Incubation with anti-b3 antibodies decreased drastically the number of
cells and cell size; no effect was observed by incubating with anti-b1
antibodies whereas the number of cells was drastically reduces using anti-b3
Reproduced with permission from ref. 62 and 68.
Table 1 Integrin association with GFs and biological eﬀects. a5b1 and avb3
have been identified to cooperate with GFs to enhance biological eﬀects.
Contradictory results that involve these receptors have been identified
Integrin GF Synergistic eﬀect
a5b1 BMP-2/PDGF Osteogenesis
62
a5b1 PDGF Stem cell recruitment
62
a5b1 VEGF Organisation of endothelial cells and
wound healing62
a5b1 BMP-2 Osteogenesis via Smad signalling
69
avb3 VEGF Limited angiogenic response
65
avb3 PDGF/FGF Wound healing
66
avb3 BMP-2 Osteogenesis via Smad cascades
68
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fibronectin secreted by cells was actually the ligand for avb3.
They suggested that avb3 integrin bound to (cell-secreted)
fibronectin distributed around cells. The co-localisation of
BMP-2 to the integrin binding sequence was proposed to help
elongate adhesion and drive traction-mediated cell spreading
processes.37 These last two findings we have described rather
contradict previous results by Martino et al. where the role of
a5b1 was predominant over avb3.
62 Together this shows that this
is likely a complex story with much further work needed.
One should note, however, that there are fundamental
conceptual diﬀerences in material systems used to present
GFs in ref. 68 and 62: while Martino et al. engineered a system
which contained integrin binding (FNIII9–10) as well as GF
binding regions (FNIII12–14) to target a5b1 and not avb3; the
layer-by-layer material system used by Albiges-Rizo et al. was
designed to present surface-bound BMP-2.68 The question
arises whether the role of vitronectin should have been con-
sidered in the attempt to understand this system, as it is known
that vitronectin is present in high amount in the serum
included in the culture medium and also secreted by cells.70
That the presentation of GFs bound to the ECM rather than
in soluble format is essential to enhance the eﬃciency of GFs
was demonstrated by engineering GFs with super-aﬃnity to the
ECM. Martino et al. discovered a domain in placenta growth
factor-2 (PlGF2123–144) that binds strongly to a large number of
ECM proteins, including fibronectin, vitronectin, fibrinogen
and collagen I. Then, PDGF-BB was modified to have
PlGF2123–144 fused to GFs and topically applied in a very low
concentration in vivo (B200 ng). This led to a significant faster
wound healing closure and granulation tissue. Similarly, in
the context of bone repair, PlGF2123–144 fused to BMP-2 and
PDGF-BB led to full regeneration in a critical-size calvarial
defect using low concentrations of GFs (B200 ng).20 This work
shows that in the clinical context, the sole delivery of GFs
without a biomaterial carrier might work well as long as the GF
has been engineer to bind the host ECM and, paradoxically,
reveals the importance of GF presentation to maximise
efficiency, even if in this case GFs were delivered topically
and in solution, without carriers.20
5. Material-driven assembly of
proteins and synergistic growth factor
microenvironments
Some ECM proteins have domains to bind GFs that are hidden
in the globular conformation of the protein but become avail-
able once these proteins are incorporated into a fibrillar ECM.
This happens for example for fibronectin.71 As discussed,
FNIII12–14 is a promiscuous region to bind GFs.
37 However,
fibronectin needs to be cell-assembled into a fibrillar protein
network for these GF-binding domains to be available – this is
the natural process of cell-mediated fibronectin assembly.71
There has been significant efforts to engineer material that
assemble proteins seeking to recapitulate the ECM. Here we
show that this material-driven assembly of proteins results in
systems that promote high efficiency presentation of GFs.
5.1. Engineering protein assembly
It is known that certain materials have the ability to induce
the organisation of ECM proteins upon adsorption from
solutions.72 In particular, there has been a significant amount
of work seeking to engineer fibronectin matrices that can
recapitulate biological features of the natural protein within the
ECM.73 Designing engineered systems which are biomimetic of
the natural ECM has been a challenge in regenerative medicine
as the ECM promotes cell adhesion, migration, signalling and
controls the availability of bioactive molecules, in particular
GFs, as has been discussed.11
Fibronectin is a ubiquitous protein with globular conforma-
tion in solution but that is organised into fibrillar structures
through cell-mediated re-arrangement. This is a biologically
regulated mechanism which involves integrin binding, reorga-
nisation of the actin cytoskeleton and then, through cytoskeletal
contraction, exertion of forces upon fibronectin to open up the
molecule and present key sites for fibronectin–fibronectin inter-
actions. There is a large body of research and excellent reviews
about this physiological process of cell-mediated fibronectin
fibrillogenesis.71,74
Cell-free routes to induce fibronectin fibrillogenesis have
been proposed and strategies involve first unfolding of fibro-
nectin dimers from their globular conformation, leading to
fibronectin–fibronectin interactions and then fibril formation
in absence of cells. Routes that have been proposed in the
literature include the use of chemical agents (addition of reducing
or oxidising agents to the protein solution; use of denaturing
anionic compounds), use of peptidic fibronectin fragments; force-
based assembly, via application of mechanical tension or shear
forces; and surface-initiated assembly (see ref. 73 for a complete
classification and discussion of published methods).
In the case of surface initiated fibronectin assembly, hydro-
philic and negatively charged surfaces were shown to promote
the extension of fibronectin upon adsorption, whereas hydro-
phobic surfaces provoked the disruption of the secondary
structures of the protein.64,75 Pernodet et al. showed that
interactions of sulphonated polystyrene with the III12–14 modules
of fibronectin unfold the molecule and trigger the process of
fibronectin assembly.76 Feinberg and Parker demonstrated that
surface initiated assembly could be used to engineer multiscale,
free-standing nanofabrics using a variety of ECM proteins
(fibronectin, laminin, fibrinogen, collagens).77 Using much
simple mechanisms, we showed that certain surface chemistries –
in particular poly(alkyl acrylates) with length of side chain
above two (e.g. ethyl, butyl, hexyl) have the ability to promote
first the unfolding of fibronectin upon adsorption on the
polymer surface and the fibronectin–fibronectin interactions
leading to the organisation of fibronectin nanonetworks on the
polymer surface (Fig. 7).78–80 We have shown that this assembly
of fibronectin at the material interface depends on the under-
lying chemistry. E.g. spontaneous organisation does occur on
PEA but does not on poly(methyl acrylate) PMA, and the degree
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of fibronectin assembly and nanonetwork interconnection can
be controlled by copolymerising EA and MA (Fig. 7).81
5.2. Protein assembly and GFs
It can be asked why the assembly of fibronectin fibrils is
dependent upon the engineering of GF microenvironments?
Fibronectin contains three kinds of domains which mediate
interactions with other fibronectin molecules, other ECM
molecules and cells (Fig. 8) as we have discussed.61 Particularly,
we note the FNIII12–14 (heparin II binding region) is a highly
promiscuous ligand for GFs.37 This region is located next to the
integrin binding region (FNIII9–10) with consequence for synergistic
integrin/GF signalling. To be exploited in cell engineering, however,
the fibronectin peptide must be open, unfolded, involving the
relevant regions (Fig. 8).
We showed that poly(ethyl acrylate) induces the spontaneous
organisation of fibronectin molecules into nanonetworks79,80
and that this assembled fibronectin structure has the ability to
present BMP-2 in synergy with a5b1 integrins, i.e., the molecule
is open and the FNIII9–10 and III12–14 regions available. Indeed,
we used AFM to show that BMP-2 directly bound fibronectin
networks on PEA and then co-localisation of integrins and
GF receptors leading to enhanced canonical Smad signalling
(Fig. 8).69
Phenomenologically, the system used very low doses of
BMP-2 (25 ng ml1) to promote mesenchymal stem cell diﬀeren-
tiation in vitro towards osteogenic lineages as well as bone
regeneration in a critical size defect in the mouse radius (Fig. 9).69
The ability of the PEA-controlled fibronectin presentation to
drive paired integrin and BMP receptor localisation required to
drive synergistic signalling was shown by co-immunoprecipitation
and co-localisation of integrin b1, and the BMP-2 receptor,
BMPR1a (Fig. 9). This synergistic GF eﬀect was mediated by b1
integrins, in line with previous results using recombinant fibro-
nectin fragments in fibrin gels62 and contrarily to results with
BMP-2 in LbL films where av was suggested to be the predominant
protein – but please note that this is an area of debate.15 b1 and
BMPR1a co-localisation had clear effects on subsequent cell
signalling. It was shown that Smads were phosphorylated by
BMPR1a and then translocate into the nucleus to activate RUNX2
and supported the conclusion that enhanced canonical BMP-2
signalling was a consequence of the simultaneous occupancy of
integrins and BMP-2 receptors.
Fig. 7 Material-driven fibronectin assembly on PEA. (a) AFM picture of
fibronectin organised into nanonetworks on PEA after adsorption from a
protein solution. (b) Chemical structure of PEA and PMA. Fibronectin
assembly occurs on PEA but not on PMA notwithstanding chemical
similarities. (c) Dynamics of fibronectin assembly on PEA followed by
AFM. Individual fibronectin molecules are unfolded upon contact with
the material surface (A) and fibronectin–fibronectin interactions occur
(B and C) leading to the self-organisation into nanofibrils (D and E).
(d) Co-polymerisation of ethyl acrylate and methyl acrylate in different
rations result in controlled degree of assembly of fibronectin. Reproduced
with permission from ref. 78 and 81.
Fig. 8 Material-driven fibronectin assembly. (a) Sketch of fibronectin
which shows the three diﬀerent kind of domains with particular emphasis
on III9–10 (which contains RGD and site PHSRN to promote a5b1 integrin
binding) and III12–15 (the GF binding site). (b) fibronectin assembly on the
surface of PEA promote GF sequestration and then simultaneous integrin
and GF receptor activation leading to synergistic signalling. (c) AFM images
of individual fibronectin molecules unfolded on PEA with two GF mole-
cules on top of them. An anti-GF antibody labelled with a gold nano-
particle was used to univocally identified BMP-2 (height image). Reproduced
with permission from ref. 69.
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PEA provides a highly facile coating can be applied through
several technologies to provide bioactive coatings of biomedical
devices, including complex 3D geometries by spin coating,
solvent casting and plasma polymerisation.82 This flexibility
allows us to envisage using the technology to engineer syner-
gistic GF microenvironments in a broad range of devices and
implants.
6. Conclusions and outlook
While widely employed in clinic for e.g. bone repair, the use of
GFs has been only partially successful and even controversial.
Engineering synergistic integrin GF receptor systems has the
potential to drastically reduce GF dose and topically deliver
the GFs to the site of regenerative demand, maximising eﬀects
by targeting integrins and GF receptors in synergy. Further-
more, the GFs remain bound and localized to the material and
so oﬀ target eﬀects should be reduced.
The use of GFs in biology and medicine has evolved from
uncontrolled delivery to systems that release GFs upon demand
(e.g. systems based in protein engineering that cleave GFs in
dependence of the concentration of cell-secreted proteases).
It is now accepted that presentation of GFs from ‘solid-phase’ is
more eﬃcient and somehow recapitulates the way GFs are used
by nature in the ECM. A new paradigm has emerged in which
the presentation of GFs can be engineered to promote crosstalk
with integrins, driving integrin/GF receptor synergistic singling
and maximising the eﬀect of GFs at minimal GF concentra-
tions. We envisage that the translation of these systems in
clinical applications will require simple engineering to go
through regulatory hurdles. We believe the use of simple
polymers in combination with recombinant proteins will
unlock translation in coming years.
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